Melbourne spin-out Hatchtech receives AU$12.6m for head lice treatment.

Australia-based pharmaceutical company Hatchtech, a spin-out of the University of Melbourne, has received AU$12.6m ($11.9m) for a new head lice-killing product.

The latest round was led by venture firm OneVentures, which was joined in participation by University of Melbourne, the Queensland Biotechnology Fund and spin-out focused venture fund Uniseed, and brings the company’s total venture capital and grant investments to $35.6m. The firm’s shareholders include OneVentures, Bowles, GBS Venture Partners, the University of Melbourne Endowment Trust, Queensland Biotechnology Funds, Uniseed,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?